Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 8/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.35 |
| ▸ | AR | P10275 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19256974 | 0.88 | CNR1 (0.41) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL9880939 | 0.83 | ALDH1A1 (0.42) | SMN1; SMN2NPC1RAB9ALMNAESR1 | |
| SCHEMBL19256867 | 0.79 | MAPK1 (0.37) | MAPK1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL12727818 | 0.77 | NPC1 (0.36) | MAPK1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL9883152 | 0.73 | TRPA1 (0.42) | SMN1; SMN2NPC1RAB9ALMNAMEN1 | |
| SCHEMBL13829913 | 0.72 | CYP1A2 (0.42) | LMNAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL19256970 | 0.72 | CNR2 (0.38) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL19010378 | 0.71 | NPC1 (0.50) | MAPK1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL21083218 | 0.71 | CYP1A2 (0.47) | MAPK1SMN1; SMN2NPC1RAB9ALMNA | |
| SCHEMBL10224681 | 0.71 | PLAU (0.47) | MAPK1SMN1; SMN2NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174017-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215749-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | MAPK1 221/4885SMN1; SMN2 2657/4885NPC1 522/4885 |
| US-10174017-B2 | Dual mechanism inhibitors for the treatment of disease | RHOA, SLC6A2, ROCK2 | MAPK1 221/4885SMN1; SMN2 2657/4885NPC1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.